364 related articles for article (PubMed ID: 32114682)
21. A dosimetry procedure for organs-at-risk in
Marin G; Vanderlinden B; Karfis I; Guiot T; Wimana Z; Reynaert N; Vandenberghe S; Flamen P
Phys Med; 2018 Dec; 56():41-49. PubMed ID: 30527088
[TBL] [Abstract][Full Text] [Related]
22. Tumoral fibrosis effect on the radiation absorbed dose of (177)Lu-Tyr(3)-octreotate and (177)Lu-Tyr(3)-octreotate conjugated to gold nanoparticles.
Azorín-Vega EP; Zambrano-Ramírez OD; Rojas-Calderón EL; Ocampo-García BE; Ferro-Flores G
Appl Radiat Isot; 2015 Jun; 100():96-100. PubMed ID: 25305748
[TBL] [Abstract][Full Text] [Related]
23. Dosimetric analysis of patients with gastro entero pancreatic neuroendocrine tumors (NETs) treated with PRCRT (peptide receptor chemo radionuclide therapy) using Lu-177 DOTATATE and capecitabine/temozolomide (CAP/TEM).
Thakral P; Sen I; Pant V; Gupta SK; Dureja S; Kumari J; Kumar S; Un P; Malasani V
Br J Radiol; 2018 Nov; 91(1091):20170172. PubMed ID: 30028180
[TBL] [Abstract][Full Text] [Related]
24. Consequences of meta-stable (177m)Lu admixture in (177)Lu for patient dosimetry.
Konijnenberg MW
Curr Radiopharm; 2015; 8(2):145-9. PubMed ID: 25771362
[TBL] [Abstract][Full Text] [Related]
25. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
26. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
[TBL] [Abstract][Full Text] [Related]
27. Comparison of voxel S-value methods for personalized voxel-based dosimetry of
Kim KM; Lee MS; Suh MS; Selvam HSMS; Tan TH; Cheon GJ; Kang KW; Lee JS
Med Phys; 2022 Mar; 49(3):1888-1901. PubMed ID: 35014699
[TBL] [Abstract][Full Text] [Related]
28. The Influence of Early Measurements Onto the Estimated Kidney Dose in [(177)Lu][DOTA(0),Tyr(3)]Octreotate Peptide Receptor Radiotherapy of Neuroendocrine Tumors.
Delker A; Ilhan H; Zach C; Brosch J; Gildehaus FJ; Lehner S; Bartenstein P; Böning G
Mol Imaging Biol; 2015 Oct; 17(5):726-34. PubMed ID: 25790773
[TBL] [Abstract][Full Text] [Related]
29. Dose Mapping After Endoradiotherapy with
Hänscheid H; Lapa C; Buck AK; Lassmann M; Werner RA
J Nucl Med; 2018 Jan; 59(1):75-81. PubMed ID: 28588150
[TBL] [Abstract][Full Text] [Related]
30. The predictive value of pretherapy [
Akhavanallaf A; Peterson AB; Fitzpatrick K; Roseland M; Wong KK; El-Naqa I; Zaidi H; Dewaraja YK
Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):2984-2996. PubMed ID: 37171633
[TBL] [Abstract][Full Text] [Related]
31. Dosimetry of
Violet J; Jackson P; Ferdinandus J; Sandhu S; Akhurst T; Iravani A; Kong G; Kumar AR; Thang SP; Eu P; Scalzo M; Murphy D; Williams S; Hicks RJ; Hofman MS
J Nucl Med; 2019 Apr; 60(4):517-523. PubMed ID: 30291192
[No Abstract] [Full Text] [Related]
32. Dosimetric Quantities in Neuroendocrine Tumors over Treatment Cycles with
Roth D; Gustafsson J; Warfvinge CF; Sundlöv A; Åkesson A; Tennvall J; Gleisner KS
J Nucl Med; 2022 Mar; 63(3):399-405. PubMed ID: 34272319
[TBL] [Abstract][Full Text] [Related]
33. A five-compartment biokinetic model for
Jeremic MZ; Matovic MD; Krstic DZ; Pantovic SB; Nikezic DR
Med Phys; 2018 Dec; 45(12):5577-5585. PubMed ID: 30291717
[TBL] [Abstract][Full Text] [Related]
34. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy.
Sainz-Esteban A; Prasad V; Schuchardt C; Zachert C; Carril JM; Baum RP
Eur J Nucl Med Mol Imaging; 2012 Mar; 39(3):501-11. PubMed ID: 22183108
[TBL] [Abstract][Full Text] [Related]
35. 177Lu-DOTATATE Peptide Receptor Radionuclide Therapy: Dose Response in Small Intestinal Neuroendocrine Tumors.
Jahn U; Ilan E; Sandström M; Garske-Román U; Lubberink M; Sundin A
Neuroendocrinology; 2020; 110(7-8):662-670. PubMed ID: 31597134
[TBL] [Abstract][Full Text] [Related]
36. 4D SPECT/CT acquisition for 3D dose calculation and dose planning in (177)Lu-peptide receptor radionuclide therapy: applications for clinical routine.
Kairemo K; Kangasmäki A
Recent Results Cancer Res; 2013; 194():537-50. PubMed ID: 22918781
[TBL] [Abstract][Full Text] [Related]
37. Preliminary data on biodistribution and dosimetry for therapy planning of somatostatin receptor positive tumours: comparison of (86)Y-DOTATOC and (111)In-DTPA-octreotide.
Förster GJ; Engelbach MJ; Brockmann JJ; Reber HJ; Buchholz HG; Mäcke HR; Rösch FR; Herzog HR; Bartenstein PR
Eur J Nucl Med; 2001 Dec; 28(12):1743-50. PubMed ID: 11734910
[TBL] [Abstract][Full Text] [Related]
38. Comparison of internal dose estimates obtained using organ-level, voxel S value, and Monte Carlo techniques.
Grimes J; Celler A
Med Phys; 2014 Sep; 41(9):092501. PubMed ID: 25186410
[TBL] [Abstract][Full Text] [Related]
39. Dosimetric model for locoregional treatments of brain tumors with 90Y-conjugates: clinical application with 90Y-DOTATOC.
Ferrari M; Cremonesi M; Bartolomei M; Bodei L; Chinol M; Fiorenza M; Tosi G; Paganelli G
J Nucl Med; 2006 Jan; 47(1):105-12. PubMed ID: 16391194
[TBL] [Abstract][Full Text] [Related]
40. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study.
Baum RP; Kluge AW; Kulkarni H; Schorr-Neufing U; Niepsch K; Bitterlich N; van Echteld CJ
Theranostics; 2016; 6(4):501-10. PubMed ID: 26941843
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
